Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 10,971 | 7,179 | 9,005 | 3,318 | 3,460 |
Gross Profit | 10,971 | 7,179 | 9,005 | 3,318 | 3,460 |
Operating Expenses | 51,292 | 49,380 | 51,140 | 41,050 | 43,603 |
Operating Income | -40,321 | -42,201 | -42,135 | -37,732 | -40,143 |
Other Income | -6,330 | -1,735 | -80 | 424 | 298 |
Pre-tax Income | -46,651 | -43,936 | -42,215 | -37,308 | -39,845 |
Income Tax | 9 | N/A | N/A | N/A | N/A |
Net Income Continuous | -46,660 | -43,936 | -42,211 | -37,308 | -39,845 |
Net Income | $-46,660 | $-43,936 | $-42,211 | $-37,308 | $-39,845 |
EPS Basic Total Ops | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
EPS Basic Continuous Ops | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
EPS Diluted Total Ops | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
EPS Diluted Continuous Ops | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
EPS Diluted Before Non-Recurring Items | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
EBITDA(a) | $-42,203 | $-44,564 | $-44,685 | $-40,133 | $-41,739 |